Immulina Liquid contains Pidotimod 400 mg, a synthetic dipeptide molecule with immunostimulant properties designed to enhance the body's natural defense mechanisms. It is indicated for use as an adjunct in the prevention and treatment of recurrent respiratory tract infections, particularly in patients with compromised immune responses or chronic respiratory conditions. Pidotimod acts by modulating both innate and adaptive immunity, promoting the activation and proliferation of T-lymphocytes, enhancing macrophage phagocytic activity, and stimulating the production of cytokines that facilitate immune response. This immunomodulatory effect helps reduce the frequency and severity of infections, improving patient outcomes. Immulina Liquid is suitable for pediatric and adult populations, offering an oral liquid formulation that ensures ease of administration and optimal bioavailability. The product should be used under medical supervision, with dosing tailored to individual patient needs and clinical conditions. Commonly, it is administered as a short course during periods of increased susceptibility to infections or as a preventive measure in recurrent cases. Adverse effects are generally mild and infrequent but may include gastrointestinal discomfort or allergic reactions. Immulina Liquid represents a valuable therapeutic option for supporting immune function in vulnerable patients.